Change in hemoglobin in adults with PK deficiency treated with mitapivat versus placebo on the ACTIVATE T trial. (A) Hemoglobin response, defined as a hemoglobin increase from baseline of ≥1.5 g/dL that was sustained at 2 or more scheduled assessments. Each bar represents an individual patient who was assigned to receive either mitapivat or placebo. (B) The least-squares mean (LSM) change from baseline in the hemoglobin level in the 2 groups during the trial period. The error bars indicate the standard error. From The New England Journal of Medicine, H Al-Samkari et al., Mitapivat versus Placebo for Pyruvate Kinase Deficiency, 386(15):1432-1442.³⁰  Copyright 2022 Massachusetts Medical Society. Reprinted with permission.